2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. Itk
  5. Itk Inhibitor

Itk Inhibitor

Itk Inhibitors (14):

Cat. No. Product Name Effect Purity
  • HY-11092
    BMS-509744
    		Inhibitor 98.09%
    BMS-509744 is a potent, selective and ATP competitive Itk inhibitor with an IC50 of 19 nM.
  • HY-12680
    PRN694
    		Inhibitor 99.36%
    PRN694 is an irreversible, highly selective and potent covalent interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) dual inhibitor with IC50s of 0.3 nM and 1.4 nM, respectively. PRN694 exhibits extended target residence time on ITK and RLK, enabling durable attenuation of effector cells in vitro and in vivo.
  • HY-109078
    Vecabrutinib
    		Inhibitor 99.85%
    Vecabrutinib (SNS-062) is a potent, noncovalent BTK and ITK inhibitor, with Kd values of 0.3 nM and 2.2 nM, respectively. Vecabrutinib shows an IC50 of 24 nM for ITK.
  • HY-108691
    PF-06465469
    		Inhibitor 99.48%
    PF-06465469 is a covalent inhibitor of ITK with an IC50 of 2 nM.
  • HY-150023
    BI-1622
    		Inhibitor 98.97%
    BI-1622 is an orally active, potent and highly selective HER2 (ERBB2) inhibitor, with an IC50 of 7 nM. BI-1622 shows greater than 25-fold selectivity over EGFR. BI-1622 shows high antitumor efficacy in vivo in xenograft mouse tumor models with engineered H2170 and PC9 cells and had a favorable agent metabolism and pharmacokinetics profile.
  • HY-150298
    Soquelitinib
    		Inhibitor
    Soquelitinib (CPI-818) is a highlyl selective covalent ITK inhibitor. Soquelitinib decreases DNA replication and cell cycle signaling.
  • HY-128726
    ITK inhibitor 2
    		Inhibitor 99.66%
    ITK inhibitor 2 is a interleukin-2-inducible T-cell kinase (ITK) inhibitor extracted from patent WO2011065402A1, compound 4, with an IC50 of 2 nM.
  • HY-12410
    GNE-9822
    		Inhibitor
    GNE-9822 is a potent, orally active and selective ITK inhibitor with a Ki value of 0.7 nM, and an EC50 value of 354.5 nM. GNE-9822 has good ADME properties. GNE-9822 can be used in research of asthma.
  • HY-146672
    ITK inhibitor 6
    		Inhibitor
    ITK inhibitor 6 (compound 43) is a potent and selective ITK inhibitor with IC50s of 4 nM, 133 nM, 320 nM, 2360 nM, 155 nM for ITK, BTK, JAK3, EGFR, LCK, respectively. ITK inhibitor 6 inhibits phosphorylation of PLCγ1 and ERK1/2. ITK inhibitor 6 shows antiproliferative activities.
  • HY-146671
    ITK inhibitor 5
    		Inhibitor
    ITK inhibitor 5 (compound 27) is a potent and selective ITK inhibitor with IC50s of 5.6, 25 nM for ITK, BTK, respectively.
  • HY-141864
    ITK/TRKA-IN-1
    		Inhibitor
    ITK/TRKA-IN-1 is a dual inhibitor of IL-2-inducible T-cell kinase (ITK) and tropomyosin receptor kinase A (TRKA) with an IC50 value of 1.0 nM and 96 % inhibition, respectively.
  • HY-120559
    GSK-2250665A
    		Inhibitor
    GSK-2250665A (Compound 13) is a selective Itk inhibitor with a pKi of 9.2.
  • HY-143901
    EGFR-IN-40
    		Inhibitor
    EGFR-IN-40 (compound 3z) is a potent BTK, EGFR, and ITK inhibitor with IC50 values of 1.2 nM, 5.3 nM, and 46.1 nM, respectively.
  • HY-13232
    ITK antagonist
    		Inhibitor
    ITK antagonist (compound 10 n) is a potent, orally active and selective ITK (Interleukin-2 inducible T-cell kinase) antagonist (IC50=1 and 20 nM in different assays). ITK antagonist inhibits insulin receptor kinase (IRK) with an IC50 of 160 nM.